Neurocrine Biosciences, Inc. (NBIX)
Automate Your Wheel Strategy on NBIX
With Tiblio's Option Bot, you can configure your own wheel strategy including NBIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NBIX
- Rev/Share 26.9889
- Book/Share 30.2173
- PB 4.9647
- Debt/Equity 0.1426
- CurrentRatio 3.3831
- ROIC 0.1033
- MktCap 14915820111.0
- FreeCF/Share 5.9668
- PFCF 25.1489
- PE 34.8411
- Debt/Assets 0.1004
- DivYield 0
- ROE 0.1582
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NBIX | Citigroup | -- | Buy | -- | $175 | Oct. 21, 2025 |
| Initiation | NBIX | Truist | -- | Buy | -- | $163 | July 21, 2025 |
| Initiation | NBIX | Goldman | -- | Buy | -- | $182 | July 10, 2025 |
| Upgrade | NBIX | Needham | Hold | Buy | -- | $138 | April 15, 2025 |
| Upgrade | NBIX | RBC Capital Mkts | Sector Perform | Outperform | -- | $137 | April 14, 2025 |
| Initiation | NBIX | Deutsche Bank | -- | Hold | -- | $138 | Feb. 11, 2025 |
| Resumed | NBIX | Raymond James | -- | Outperform | -- | $155 | Oct. 10, 2024 |
| Upgrade | NBIX | Piper Sandler | Neutral | Overweight | $131 | $159 | Aug. 29, 2024 |
News
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Published: February 25, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 25, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle Gano, Chief Financial Officer Matt Abernethy, and Chief Commercial Officer Eric Benevich will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 11:10 AM Eastern Time in Boston.
Read More
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.
Read More
About Neurocrine Biosciences, Inc. (NBIX)
- IPO Date 1996-05-23
- Website https://www.neurocrine.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kyle W. Gano
- Employees 1800